Sexual wellness for women in Atlanta: a physician's guide

Why this is medical, not personal

For decades, women's sexual concerns were treated as relationship issues, emotional problems, or "just getting older." We now understand that many — perhaps most — have specific physiological drivers that respond to specific treatments. Hormone shifts, neurochemistry, medication side effects, pelvic-floor changes, and metabolic factors all play measurable roles.

The reframe matters because it changes the question. Instead of "what's wrong with me?" the right question is: "what's the contributing physiology, and which interventions have evidence?"

The answer is often more interventions than you'd think — and a physician-led conversation is the place to map them.

The five most common concerns we see

1. Low or absent desire (HSDD) — Hypoactive Sexual Desire Disorder is a recognized clinical diagnosis affecting roughly 10% of premenopausal women. The American Psychiatric Association and FDA both treat it as a real condition with FDA-approved pharmacological options.
2. Perimenopause and menopause symptoms — falling estrogen and testosterone (yes, women have testosterone, and it matters here) cause reduced desire, vaginal dryness, painful sex, and changes in arousal capacity. Typical onset is late 30s through mid 50s.
3. Postpartum changes — temporary reductions in libido and lubrication are universal and physiological; persistent issues past 6–12 months postpartum warrant evaluation. Breastfeeding particularly suppresses estrogen.
4. Medication-induced changes — SSRIs, SNRIs, hormonal contraceptives, and certain blood-pressure drugs are well-documented contributors. Often a medication adjustment (with the prescribing physician) is the simplest fix.
5. Pain with intercourse (dyspareunia) — usually has a specific cause (vaginal atrophy, pelvic-floor dysfunction, vulvar conditions, prior surgery). Most are treatable; many are missed because they're not asked about.

What a proper workup looks like

A meaningful sexual wellness consultation includes:

• A confidential history — onset, pattern, what's changed, related symptoms (fatigue, mood, sleep, cycles), partner dynamics if relevant
• Medical and medication review — including a focused look at any prescriptions known to affect libido or arousal
• Hormone panel — total and free testosterone, estradiol, SHBG, FSH, LH, thyroid (TSH, free T4), prolactin, and DHEA-S. These are inexpensive and informative.
• Symptom-specific exam — pelvic exam if pain or vaginal symptoms are reported; otherwise consultation-only is appropriate. Always your choice.
• Treatment plan discussion — what's evidence-based, what's likely to work for your situation, what it costs, and what timeline to expect

Evidence-based treatments

For HSDD (low desire)

• Bremelanotide (PT-141 / Vyleesi) — FDA-approved injectable peptide for premenopausal HSDD. Acts on central nervous system desire pathways (different mechanism than sildenafil-class drugs). Used on-demand. Strong clinical trial data.
• Flibanserin (Addyi) — FDA-approved daily oral medication for HSDD. Works on serotonin/dopamine receptors. Can interact with alcohol; not for everyone but transformative for some.
• Testosterone therapy (off-label) — low-dose testosterone has growing evidence in postmenopausal women with HSDD. Discussed individually based on labs, history, and goals.

For perimenopause / menopause

• Local estrogen therapy — vaginal cream, ring, or tablet. Highly effective for vaginal dryness and atrophy with minimal systemic exposure. Often the single most impactful intervention for this symptom cluster.
• Systemic hormone therapy — when appropriate, addresses the broader symptom picture including hot flashes, sleep, and mood. Always individualized; not for everyone.
• Non-hormonal vaginal moisturizers — for clients who can't or don't want to use estrogen.

For pain or pelvic-floor concerns

• Pelvic-floor physical therapy — referral to a specialist; remarkably effective for many causes of dyspareunia.
• Topical anesthetic protocols — short-term tools while addressing the underlying cause.
• Treatment of underlying conditions — vulvar dermatoses, lichen sclerosus, atrophy, etc.

Adjunct: lifestyle factors that genuinely matter

Sleep, stress, alcohol use, exercise, and weight management all measurably affect sexual function. We discuss these alongside any pharmacological options — not as substitutes, but as multipliers.

What a consultation looks like

Most clients tell us they were nervous to bring it up. Here's what to expect at Majspa to take the guesswork out:

1. Initial intake can happen by phone or telehealth if that's easier than coming in. Some clients prefer this for the first conversation.
2. In-person visit is private and unhurried — you'll be seen by Dr. Msimanga directly, not handed off to multiple providers.
3. Lab work if indicated, drawn at the studio or at a partner lab.
4. Discussion of options: what's likely to work for you, what each costs, what the timeline looks like.
5. Plan: prescriptions written if appropriate; follow-up scheduled.
6. Confidentiality: nothing is shared outside your medical record without your explicit written consent.

Cost

At Majspa Aesthetics in Marietta:

• Initial consultation: complimentary for new clients
• Lab work: typically $150–$300 depending on which panels (some insurance may cover)
• PT-141 / bremelanotide: from $150–$300 per month depending on dose and pharmacy
• Flibanserin: variable; often covered by insurance with prior authorization
• Hormone therapy: from $50–$200 per month depending on form and dose
• Local vaginal estrogen: typically $30–$80 per month with insurance

CareCredit financing is available for treatment packages. We confirm exact pricing during your consultation.

FAQ

---

Continue reading

• Peptide therapy guide
• Medical weight loss in Atlanta
• Hair restoration in Atlanta
• Med spa in Marietta, GA — overview
• Meet your provider — Dr. Nokuthula Msimanga, MD

Sources & further reading

• Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):899–908.
• Davis SR, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
• Pinkerton JV, et al. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
• ACOG — Your Sexual Health
• U.S. FDA — Bremelanotide approval